OBX-13 series (Oncobix)

N/A

Report date: 2025/03/19 11:43:21

NME

Base Information

Drug NameOBX-13 series (Oncobix)

Drug Alias NameALK/ROS1/RET fusion inhibitors (Oncobix)

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionProto-oncogene tyrosine-protein kinase ROS inhibitorsTyrosine-protein kinase receptor RET inhibitorsAnaplastic lymphoma kinase inhibitors

TargetsAnaplastic lymphoma kinaseTyrosine-protein kinase receptor RETProto-oncogene tyrosine-protein kinase ROS

Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesOncobix Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesOncobix Co Ltd

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell Lung

Inactive IndicationsN/A

Other Information

ATC CodeN/A